D Bouros, S Schiza, G Patsourakis, G Chalkiadakis, P Panagou and NM Siafakas
Department of Thoracic Medicine, Medical School, University of Crete, and University General Hospital, Heraklion, Greece. bouros@athina.edu.uch.gr

Intrapleural administration of fibrinolytics has been shown in small numbers of patients with complicated parapneumonic effusions (CPE) and pleural empyema to be effective and relatively safe. Although streptokinase (SK) is recommended as the fibrinolytic of choice, there are no comparative studies among fibrinolytics. We therefore compared the efficacy, safety, and the cost of treatment two of the most used thrombolytics, SK and urokinase (UK). Fifty consecutive patients with CPE or empyema were randomly allocated to receive either SK (25 patients) or UK, in a double-blind fashion. All patients had inadequate drainage through chest tube (< 70 ml/24 h). Both drugs were diluted in 100 ml normal saline and were infused intrapleurally through the chest tube in a daily dose of 250,000 IU of SK or 100,000 IU of UK. The chest tube was clamped for 3 h after instillation. Response was assessed by clinical outcome, fluid drainage, chest radiography, pleural ultrasound, and/or computed tomography. Clinical and radiologic improvement was noted in all but two patients in each group, who required surgical intervention. The mean volume drained during the first 24 h after instillation was significantly increased; 380 +/- 99 ml for the SK group (p < 0.001) and 420.8 +/- 110 ml for the UK group (p < 0.001). The total volume (mean +/- SD) of fluid drained after treatment was 1,596 +/- 68 ml for the SK group, and 1,510 +/- 55 ml for the UK group (p > 0.05). The SK instillations (mean +/- SD) were 6 +/- 2.16 (range, 3 to 10) and those of UK 5.92 +/- 2.05 (range, 3 to 8). High fever as adverse reaction to SK was observed in two patients. The total cost of the drug in the UK group was two times higher than that of SK ($180 +/- 47 for SK and $320 +/- 123 for UK). The mean total hospital stay after beginning fibrinolytic therapy was 11.28 +/- 2.44 d (range, 7 to 15) for the SK group and 10.48 +/- 2.53 d (range, 6 to 18) for the UK group (p = 0.32). We conclude that intrapleural SK or UK is an effective adjunct in the management of parapneumonic effusions and may reduce the need for surgery. UK could be the thrombolytic of choice given the potentially dangerous allergic reactions to SK and relatively little higher cost of UK.

This article has been cited by other articles:

				D. J. Boffa, D. P. Mason, J. W. Su, S. C. Murthy, J. Feng, A. M. McNeill, M. M. Budev, A. C. Mehta, and G. B. Pettersson Decortication After Lung Transplantation Ann. Thorac. Surg., March 1, 2008; 85(3): 1039 - 1043. [Abstract] [Full Text] [PDF]

				S. Idell, T. Allen, S. Chen, K. Koenig, A. Mazar, and A. Azghani Intrapleural activation, processing, efficacy, and duration of protection of single-chain urokinase in evolving tetracycline-induced pleural injury in rabbits Am J Physiol Lung Cell Mol Physiol, January 1, 2007; 292(1): L25 - L32. [Abstract] [Full Text] [PDF]

				Z. Zhu, M. L. Hawthorne, Y. Guo, W. Drake, S. Bilaceroglu, H. L. Misra, and R. W. Light Tissue Plasminogen Activator Combined With Human Recombinant Deoxyribonuclease Is Effective Therapy for Empyema in a Rabbit Model Chest, June 1, 2006; 129(6): 1577 - 1583. [Abstract] [Full Text] [PDF]

				Managing empyema in adults DTB, March 1, 2006; 44(3): 17 - 21. [Abstract] [Full Text] [PDF]

				D. Bouros, K. M Antoniou, and R. W Light Intrapleural streptokinase for pleural infection BMJ, January 21, 2006; 332(7534): 133 - 134. [Full Text] [PDF]

				R. W. Light Parapneumonic effusions and empyema. Proceedings of the ATS, January 1, 2006; 3(1): 75 - 80. [Abstract] [Full Text] [PDF]

				G. Cheng and J. R.E. Vintch A Retrospective Analysis of the Management of Parapneumonic Empyemas in a County Teaching Facility From 1992 to 2004 Chest, November 1, 2005; 128(5): 3284 - 3290. [Abstract] [Full Text] [PDF]

				C. K. Katikireddy, D. S. Dube, A. H. Diacon, C. F.N. Koegelenberg, C. T. Bolliger, U. W. Rosa, D. Bouros, R. J.O. Davies, N. A. Maskell, and A. J. Nunn A Trial of Intrapleural Streptokinase N. Engl. J. Med., May 26, 2005; 352(21): 2243 - 2245. [Full Text] [PDF]

				N. A. Maskell, C. W.H. Davies, A. J. Nunn, E. L. Hedley, F. V. Gleeson, R. Miller, R. Gabe, G. L. Rees, T. E.A. Peto, M. A. Woodhead, et al. U.K. Controlled Trial of Intrapleural Streptokinase for Pleural Infection N. Engl. J. Med., March 3, 2005; 352(9): 865 - 874. [Abstract] [Full Text] [PDF]

				I M Balfour-Lynn, E Abrahamson, G Cohen, J Hartley, S King, D Parikh, D Spencer, A H Thomson, D Urquhart, and on behalf of the Paediatric Pleural Diseases Subco BTS guidelines for the management of pleural infection in children Thorax, February 1, 2005; 60(suppl_1): i1 - i21. [Full Text] [PDF]

				G. Ekingen, B. H. Guvenc, S. Sozubir, A. Tuzlaci, and U. Senel Fibrinolytic treatment of complicated pediatric thoracic empyemas with intrapleural streptokinase Eur. J. Cardiothorac. Surg., September 1, 2004; 26(3): 503 - 507. [Abstract] [Full Text] [PDF]

				Y. C. G. Lee Ongoing Search for Effective Intrapleural Therapy for Empyema: Is Streptokinase the Answer? Am. J. Respir. Crit. Care Med., July 1, 2004; 170(1): 1 - 2. [Full Text] [PDF]

				A. H. Diacon, J. Theron, M. M. Schuurmans, B. W. Van de Wal, and C. T. Bolliger Intrapleural Streptokinase for Empyema and Complicated Parapneumonic Effusions Am. J. Respir. Crit. Care Med., July 1, 2004; 170(1): 49 - 53. [Abstract] [Full Text] [PDF]

				C.-T. Yao, J.-M. Wu, C.-C. Liu, M.-H. Wu, H.-Y. Chuang, and J.-N. Wang Treatment of Complicated Parapneumonic Pleural Effusion With Intrapleural Streptokinase in Children Chest, February 1, 2004; 125(2): 566 - 571. [Abstract] [Full Text] [PDF]

				T. L. Ray, J. W. Berkenbosch, P. Russo, and J. D. Tobias Tissue Plasminogen Activator as an Adjuvant Therapy for Pleural Empyema in Pediatric Patients J Intensive Care Med, January 1, 2004; 19(1): 44 - 50. [Abstract] [PDF]

				R. G. Wells and P. L. Havens Intrapleural Fibrinolysis for Parapneumonic Effusion and Empyema in Children Radiology, August 1, 2003; 228(2): 370 - 378. [Abstract] [Full Text] [PDF]

				C W H Davies, F V Gleeson, and R J O Davies BTS guidelines for the management of pleural infection Thorax, May 1, 2003; 58(90002): ii18 - 28. [Full Text]

				C. A Walker, M. B. Shirk, M. M Tschampel, and J. A Visconti Intrapleural Alteplase in a Patient with Complicated Pleural Effusion Ann. Pharmacother., March 1, 2003; 37(3): 376 - 379. [Abstract] [Full Text] [PDF]

				C. P. Reznikoff, J. T. Fish, and D. B. Coursin Pericardial Infusion of Tissue Plasminogen Activator in Fibropurulent Pericarditis J Intensive Care Med, January 1, 2003; 18(1): 47 - 51. [Abstract] [PDF]

				A H Thomson, J Hull, M R Kumar, C Wallis, and I M Balfour Lynn Randomised trial of intrapleural urokinase in the treatment of childhood empyema Thorax, April 1, 2002; 57(4): 343 - 347. [Abstract] [Full Text] [PDF]

				B. Ghaye and R.F. Dondelinger Imaging guided thoracic interventions Eur. Respir. J., March 1, 2001; 17(3): 507 - 528. [Abstract] [Full Text] [PDF]

				G. L. Colice, A. Curtis, J. Deslauriers, J. Heffner, R. Light, B. Littenberg, S. Sahn, R. A. Weinstein, and R. D. Yusen Medical and Surgical Treatment of Parapneumonic Effusions : An Evidence-Based Guideline Chest, October 1, 2000; 118(4): 1158 - 1171. [Abstract] [Full Text] [PDF]

				S. Sasse, T. Nguyen, L. R. Teixeira, and R. Light The Utility of Daily Therapeutic Thoracentesis for the Treatment of Early Empyema* Chest, December 1, 1999; 116(6): 1703 - 1708. [Abstract] [Full Text] [PDF]

				D. BOUROS, S. SCHIZA, N. TZANAKIS, G. CHALKIADAKIS, J. DROSITIS, and N. SIAFAKAS Intrapleural Urokinase versus Normal Saline in the Treatment of Complicated Parapneumonic Effusions and Empyema . A Randomized, Double-Blind Study Am. J. Respir. Crit. Care Med., January 1, 1999; 159(1): 37 - 42. [Abstract] [Full Text]